Thomas Iftner

Thomas Iftner


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2015 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
TIThomas Iftner
Thomas Iftner
SBSven Becker
Sven Becker
KNKlaus-Joachim Neis
Klaus-Joachim Neis
Alejandra CastanonAlejandra Castanon
Alejandra Castanon
AIAngelika Iftner
Angelika Iftner
PSPeter Sasieni
Peter Sasieni
Testing for E6/E7 mRNA in cells infected with high-risk (HR) human papillomavirus (HPV) might improve the specificity of HPV testing for the identification of cervical precancerous lesions. Here we compared the RNA-based Aptima HPV (AHPV) assay (Hologic) and the DNA-based Hybrid Capture 2 (HC2) HPV test (Qiagen) to liquid-based cytology (LBC) for women undergoing routine cervical screening. A total of 10,040 women, 30 to 60 years of age, were invited to participate in the study, 9,451 of whom were included in the analysis. Specimens were tested centrally by LBC, the AHPV test, and the HC2 test, and women who tested positive on any test were referred for colposcopy. Genotyping was performed on all HR-HPV-positive samples. Test characteristics were calculated based on histological review. As a result, we identified 90 women with cervical intraepithelial neoplasia grade 2+ (CIN2+), including 43 women with CIN3+. Sensitivity differences between the AHPV test and the HC2 test in detecting CIN2+ ( P = 0.180) or CIN3+ ( P = 0.0625) lesions were statistically nonsignificant. Of three CIN3 cases that were missed with the AHPV test, two cases presented lesion-free cones and one had a non-HR HPV67 infection. The specificity (<CIN2) and positive predictive value (CIN2+) of the AHPV test were significantly higher (both P < 0.001) than those of the HC2 test. The overall agreement between the tests was substantial (κ = 0.77). Finally, we present results for several possible triage strategies, based on the primary screening test being either the AHPV test or the HC2 test. In summary, the AHPV assay is both specific and sensitive for the detection of high-grade precancerous lesions and may be used in primary cervical cancer screening for women ≥30 years of age.

1 March 2016 in Journal of Clinical Virology
Verified
Journal Article
Open access
JHJuliane Haedicke
Juliane Haedicke
TIThomas Iftner
Thomas Iftner
This comprehensive review compiles published data from 62 original articles comparing different HPV tests and one meta-analysis on the clinical performance of the Aptima HR HPV (AHPV) assay in either screening or referral populations as well as for the purpose of test of cure. A number of publications with technical issues were also considered. Besides a brief introduction in the development of E6/E7 mRNA testing, the review summarizes data on analytical sensitivies and specificities, as well as on clinical sensitivity, specificity, NPV and PPV with histological endpoints CIN2+ and CIN3+, where available. Although most studies were of cross-sectional design, five studies with a longitudinal prospective design or component were identified. In addition to the study design, sample size, age and CIN2/3+ prevalence of the respective cohort are listed. This allows direct comparison of the published data in the respective groups. One major outcome of this review is the remarkably stable similar sensitivities of AHPV and HC2 independent from study design for detection of CIN2/3+ combined with a higher specificity of the AHPV. The second outcome was the longitudinal predictive value derived from registry linkage and other prospective studies that would support the applicability of the AHPV test in primary screening with at least a three year screening interval.

24 September 2018 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
FSFreja Lærke Sand
Freja Lærke Sand
CMChristian Munk
Christian Munk
KFKirsten Frederiksen
Kirsten Frederiksen
JJJette Junge
Jette Junge
TIThomas Iftner
Thomas Iftner
SKSusanne K. Kjaer
Susanne K. Kjaer

20 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
DBDaniel J. Butler
Daniel J. Butler
CMChristopher Mozsary
Christopher Mozsary
CMCem Meydan
Cem Meydan
DDDavid C Danko
David C Danko
JFJonathan Foox
Jonathan Foox
Christopher MasonChristopher Mason
Christopher Mason
The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has caused thousands of deaths worldwide, including >18,000 in New York City (NYC) alone. The sudden emergence of this pandemic has highlighted a pressing clinical need for rapid, scalable diagnostics that can detect infection, interrogate strain evolution, and identify novel patient biomarkers. To address these challenges, we designed a fast (30-minute) colorimetric test (LAMP) for SARS-CoV-2 infection from naso/oropharyngeal swabs, plus a large-scale shotgun metatranscriptomics platform (total-RNA-seq) for host, bacterial, and viral profiling. We applied both technologies across 857 SARS-CoV-2 clinical specimens and 86 NYC subway samples, providing a broad molecular portrait of the COVID-19 NYC outbreak. Our results define new features of SARS-CoV-2 evolution, nominate a novel, NYC-enriched viral subclade, reveal specific host responses in interferon, ACE, hematological, and olfaction pathways, and examine risks associated with use of ACE inhibitors and angiotensin receptor blockers. Together, these findings have immediate applications to SARS-CoV-2 diagnostics, public health, and new therapeutic targets.

1 March 2017 in Virus Research
Verified
Journal Article
Closed access
TIThomas Iftner
Thomas Iftner
JHJuliane Haedicke-Jarboui
Juliane Haedicke-Jarboui
SWShwu-Yuan Wu
Shwu-Yuan Wu
CCCheng-Ming Chiang
Cheng-Ming Chiang

17 September 2010 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
TIThomas Iftner
Thomas Iftner
SESonja Eberle
Sonja Eberle
AIAngelika Iftner
Angelika Iftner
BHBarbara Holz
Barbara Holz
NBNorbert Banik
Norbert Banik
ASAnja‐Natascha Straube
Anja‐Natascha Straube